Literature DB >> 12137808

Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells.

Peter B Ehmer1, Matthias Bureik, Rita Bernhardt, Ursula Müller, Rolf W Hartmann.   

Abstract

Aldosterone synthase (CYP11B2) is a mitochondrial cytochrome P450 enzyme catalyzing the last steps of aldosterone production in the adrenal cortex. A new pharmacological approach for the treatment of the aldosterone induced effects in congestive heart failure and all forms of hyperaldosteronism could be the use of CYP11B2 inhibitors. In search for such compounds, it was our goal to develop a cellular enzyme assay suitable for screening high numbers of compounds. An assay procedure for the evaluation of inhibitors using the human CYP11B2 expressed in fission yeast Schizosaccharomyces pombe was established and a series of 10 compounds was tested in this whole cellular system. Human 11beta-hydroxylase (CYP11B1), which catalyzes the production of glucocorticoids, shows more than 90% homology compared to human CYP11B2. As this enzyme should not be affected, strong inhibitors of CYP11B2 have to be tested for selectivity. For that purpose, an assay procedure with V79MZ cells that express human CYP11B1 and CYP11B2, respectively, was integrated into the evaluation process. Using these screening procedures a potent and rather selective non-steroidal inhibitor of human CYP11B2 was detected with an IC(50) value of 59nM. We also identified a very potent inhibitor of both enzymes showing a stronger inhibitory activity against the cortisol producing CYP11B1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12137808     DOI: 10.1016/s0960-0760(02)00056-0

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  5 in total

Review 1.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

2.  First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.

Authors:  Ulrike E Hille; Christina Zimmer; Carsten A Vock; Rolf W Hartmann
Journal:  ACS Med Chem Lett       Date:  2010-10-22       Impact factor: 4.345

3.  Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.

Authors:  Ulrike E Hille; Christina Zimmer; Jörg Haupenthal; Rolf W Hartmann
Journal:  ACS Med Chem Lett       Date:  2011-06-03       Impact factor: 4.345

4.  Pharmacophore Modeling and in Silico/in Vitro Screening for Human Cytochrome P450 11B1 and Cytochrome P450 11B2 Inhibitors.

Authors:  Muhammad Akram; Watcharee Waratchareeyakul; Joerg Haupenthal; Rolf W Hartmann; Daniela Schuster
Journal:  Front Chem       Date:  2017-12-19       Impact factor: 5.221

5.  3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2.

Authors:  Lina Yin; Qingzhong Hu; Rolf W Hartmann
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.